CIVITAS-INVESTMENT
18.6.2020 08:02:13 CEST | Business Wire | Press release
From today all the investment management activities of the Civitas Group have been brought together under the new name of Civitas Investment Management Limited (“CIM” or “the Group”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200617005883/en/
CIM is a leading impact investor specialising in government-backed real assets that produce beneficial and sustainable social outcomes. Today, CIM announces expanded client mandates with combined assets under management (“AUM”) of £2 billion.
In all of CIM’s investment activities the Group aims to achieve measurable social impact at scale whilst delivering consistent long-term return profiles for investors together with value for money for the public purse. This is reflected in better personal outcomes and an enhanced quality of life for people living in the Group’s properties.
CIM’s performance in achieving these aims is monitored by independent social impact consultants who challenge and assist CIM in its investment frameworks.
Having established a leading presence in the UK for care-based housing and healthcare CIM is now expanding further into community based infrastructure and is planning to launch in the EU during the next 12 months.
New Website
To support these plans CIM has launched a new dedicated website that outlines its activities, social objectives and profiles the range of investment strategies that are delivered for institutional investors around the world (www.civitasim.com ).
Who We Are
CIM is a pioneer in introducing ethical, long-term private capital into the affordable housing and healthcare sectors, initially in England and Wales, then more widely in the UK and now with plans to access major EU countries.
In 2016 CIM launched Civitas Social Housing PLC, (“CSH”) as the first premium London listed real estate investment trust dedicated to investing in care-based housing for working age adults with long-term healthcare needs.
CSH is now a FTSE 250 company and the leading provider of care-based community housing in the UK with a portfolio of more than 600 buildings independently valued at nearly £900 million. Located across 164 local authority areas, supported by 117 specialist care providers, and 15 housing partners CSH provides bespoke, high quality adapted homes for over 4,200 people.
Reflecting the success of the strategy shareholders recently approved an extension of the CSH investment policy to enable the fund to work directly with the NHS, with other leading care providers and with major charities to provide accommodation and other social properties, in short supply within healthcare real estate.
CIM Investment Strategies
Having commenced investing in care-based social housing, CIM has now evolved a range of four broad and complementary investment strategies as follows:
- Healthcare
- Social and Affordable Housing
- Social Infrastructure
- Urban Regeneration
Across each of the four investment strategies are common themes and investment objectives that include:
- 100% governmental income and support
- Value for money for the public purse
- Stable long-term cash generation
- Low volatility and low correlation to economic cycles
- Measurable social and ESG impact
Exclusive Partnerships
To assist in the delivery of the Group’s investment strategies CIM is pleased to have established exclusive partnerships with a number of leading investment houses and global real estate and infrastructure investors with whom CIM shares common ambitions and objectives.
Today CIM’s partners include:
- Schroders, the global investment manager responsible for more than £500 billion of client assets across multiple investment strategies. CIM and Schroders are exclusive partners delivering new care-based housing, initially for approximately 2,000 people;
- A leading Asia based global infrastructure and real estate investor has established an exclusive partnership with CIM to invest in housing based social infrastructure assets
Our Vision
The team of professionals working at CIM comes from a range of different backgrounds each offering expertise and operational experience in healthcare, social housing, real estate, social infrastructure and investment management.
They share a common conviction that responsible private capital can play a transformational role in the delivery of social assets that are themselves designed to enhance lives and communities. By investing for the long-term, with measurable social impact a fundamental requirement, the conditions are created for achieving sustainable and ethical returns for investors.
Andrew Dawber, Group Director at Civitas Investment Management Limited commented:
“We are delighted that CIM has reached an important investment milestone based on a growing number of client mandates. We are greatly encouraged by the opportunities in the near term future as we grow and build out our investment funds, deploying capital in projects in the UK, and in Europe in due course. We are experiencing strong and growing demand from portfolio managers who increasingly recognise the attractions of investing in the asset classes that CIM promotes.
We are especially proud of the team that we have built at CIM who each provide different perspectives towards the same goal, creating sustainable investment returns for the long term in projects that deliver genuine social good at a local level wherever that investment is made.”
-ENDS-
Notes to Editors:
Civitas Investment Management Limited (‘CIM’) is a leading impact investment manager that is dedicated to achieving long-term sustainable returns for the Group’s global investors by acquiring community-based assets that deliver positive social outcomes. CIM’s investments are supported by national governments and local municipalities that are themselves seeking to bring about positive societal change. CIM has an AUM of approximately £2 billion with a target to increase to £4 billion over the next two to three years following the build out of client mandates.
Among other impact investment ventures, CIM is the investment adviser to the London listed Civitas Social Housing PLC (“CSH”), the first dedicated London listed REIT to raise long-term sustainable, institutional capital to invest in care-based social homes and healthcare facilities across the UK. So far CIM has on behalf of CSH completed more than 120 individual transactions to build the largest portfolio of its kind in the UK that has been independently valued at approximately £900 million (www.civitassocialhousing.com ).
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005883/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
